Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezafungin in the Treatment of Chronic Pulmonary Aspergillosis (CPA)
NCT06794554Phase 2Active, not recruiting
- Sponsor
- Mundipharma
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of rezafungin in chronic pulmonary aspergillosis (CPA), sponsored by Mundipharma. Primary endpoint: Change from baseline in clinical and radiological response at 6 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
rezafungin
03
Conditions
chronic pulmonary aspergillosis (CPA)
Beyond the preview
Go deeper on NCT06794554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794554.